Trial Profile
A single dose, randomised, double blind, double dummy, placebo-controlled, three-period crossover clinical study, comparing the efficacy, safety and tolerability of Formoterol-HFA pMDI 12 microgram per actuation administered by means of a "spacer" device (AeroChamber Plus) with that of Formoterol-HFA pMDI 12 microgram per actuation in 5- to 12-year-old children with persistent moderate to severe asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2011
Price :
$35
*
At a glance
- Drugs Formoterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 07 Jun 2011 New trial record